Abstract Chronic Lymphocytic Leukemia (CLL) is a malignancy of mature B lymphocytes
which are highly dependent on interactions with the tissue microenvironment for their …

Over the last decade, the active role of the microenvironment in the pathogenesis of B cell
lymphomas has been recognized, delivering signals that favor clonal expansion and drug …

CD38 (also known as T10) was identified in the late 1970s in the course of pioneering work
carried out at the Dana‐Farber Cancer Center (Boston, MA) that focused on the identification …

Purpose: Daratumumab treatment results in a marked reduction of CD38 expression on
multiple myeloma cells. The aim of this study was to investigate the clinical implications and …

Purpose Although CD49d is an unfavorable prognostic marker in chronic lymphocytic
leukemia (CLL), definitive validation evidence is lacking. A worldwide multicenter analysis …

Purpose: Ibrutinib leads to a transient lymphocytosis in patients with chronic lymphocytic
leukemia (CLL) that develops within hours of starting drug and is due to the efflux of cells …

Patients with chronic lymphocytic leukemia can be divided into three categories: those who
are minimally affected by the problem, often never requiring therapy; those that initially …

Interactions between malignant B lymphocytes and the tissue microenvironment play a
major role in the pathogenesis of chronic lymphocytic leukemia (CLL) and other B-cell …

The Bruton's tyrosine kinase (BTK) inhibitor ibrutinib, which antagonizes B cell receptor
(BCR) signals, demonstrates remarkable clinical activity in chronic lymphocytic leukemia …

In chronic lymphocytic leukemia (CLL), NOTCH1 mutations have been associated with
clinical resistance to the anti-CD20 rituximab, although the mechanisms behind this peculiar …